Investing.com
Published May 30, 2025 07:32AM ET
On Friday, H.C. Wainwright reaffirmed its Buy rating and $70.00 price target for uniQure BV (NASDAQ:QURE), a biotechnology company specializing in gene therapy currently trading at $14.90 with a market capitalization of $816 million. The firm highlighted uniQure as a top pick for 2025, following the announcement of initial data from the company's Phase 1/2a trial of AMT-260, a gene therapy candidate for mesial temporal lobe epilepsy (mTLE). According to InvestingPro data, seven analysts have recently revised their earnings expectations upward for the upcoming period, suggesting growing confidence in the company's prospects.
The trial, named GenTLE, reported findings from the first mTLE patient treated with AMT-260, a one-time adeno-associated vector (AAV) in vivo gene therapy. Stifel analysts expressed optimism about the preliminary results, stating that the data, though from a single patient, are promising and warrant the continuation of the program. They noted that these early results support the inclusion of additional patients with drug-refractory mTLE, a condition currently lacking effective treatment options. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 11.99, though it operates with moderate debt levels.
The firm's analysts emphasized the significant need for new treatments in this area and suggested that if AMT-260's safety profile remains positive in further patients, uniQure is likely to proceed to the randomized Phase 2 segment of the trial in 2026. This progression could mark a substantial step forward for the company and for patients with mTLE.
H.C. Wainwright's maintained price target of $70.00 reflects confidence in uniQure's potential and the prospects of AMT-260. The firm's endorsement reiterates the belief in the company's strategy and the value of its innovative gene therapy approach.
The analyst from H.C. Wainwright concluded their commentary by reasserting their Buy rating on QURE stock, indicating a strong conviction in the company's future performance and the success of its therapeutic candidate, AMT-260. This reiteration of support from a notable firm could influence market perceptions and investor decisions regarding uniQure BV.
In other recent news, uniQure has received significant attention following the U.S. Food and Drug Administration's (FDA) granting of Breakthrough Therapy designation to its gene therapy candidate, AMT-130, for Huntington's disease. This regulatory milestone is supported by interim data from Phase I/II trials, indicating AMT-130's potential to slow disease progression. Analysts at H.C. Wainwright have reaffirmed a Buy rating with a $70 price target, highlighting the designation as a step towards an accelerated approval pathway. Additionally, Chardan Capital Markets initiated coverage with a Buy rating and a $38 price target, citing the promising potential of uniQure's gene therapy pipeline. The company is also advancing therapies for other conditions, including epilepsy and ALS.
In corporate developments, uniQure's CEO, Matthew Kapusta, has secured an amended employment agreement, detailing salary, bonuses, and severance benefits. The agreement includes provisions for long-term incentives and standard restrictive covenants. As uniQure continues its clinical trials and regulatory interactions, investors remain focused on the potential market impact of AMT-130 and other gene therapy candidates. With ongoing support from the FDA and positive analyst outlooks, uniQure's progress in gene therapy remains a key area of interest for stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.